Mark Schoenberg, Chief Medical Officer, on August 20, 2026, sold 60,677 shares in Urogen Pharma (URGN) for $2,854,853. Following the Form 4 filing with the SEC, Schoenberg has control over a total of 59,086 ordinary shares of the company, with 59,086 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1668243/000143774926028840/xslF345X05/rdgdoc.xml
Anshul Maheshwari, Chief Operating & Financial Officer, on August 19, 2026, sold 16,975 shares in Si-Bone (SIBN) for $337,138. Following the Form 4 filing with the SEC, Maheshwari has control over a total of 234,920 common shares of the company, with 234,920 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1459839/000185308926000007/xslF345X05/primarydocument.xml
Laura Francis, Director, Chief Executive Officer, on August 20, 2026, sold 55,807 shares in Si-Bone (SIBN) for $1,088,201. Following the Form 4 filing with the SEC, Francis has control over a total of 811,363 common shares of the company, with 493,900 shares held directly and 317,463 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1459839/000121880226000004/xslF345X05/primarydocument.xml
Thomas J. Cable, Director, on August 20, 2026, sold 15,000 shares in Omeros (OMER) for $276,773. Following the Form 4 filing with the SEC, Cable has control over a total of 35,067 common shares of the company, with 35,067 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1285819/000143774926028754/xslF345X05/rdgdoc.xml